anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide Lentinus edodes (Berk.) Singer with a high lentinan content in a fruit body.SOLUTION: The invention provides Lentinus edodes (Berk.) Singer having a variant exo-β-1,3-glucanase (EXG2), and in which a lentinan content in a fruit body is increased compared with conventional varieties. The invention also provides a method for producing lentinan comprising culturing Lentinus edodes (Berk.) Singer to form a fruit body and to harvest the fruit body. The method for detecting the Lentinus edodes (Berk.) Singer in which the lentinan content in the fruit body is increased compared with the conventional varieties comprises detecting the presence or absence of a substituted mutation in the amino acid residue at position 710 in the amino acid sequence of EXG2; and when the substituted mutation is present in the amino acid residue at position 710, recognizing the Lentinus edodes (Berk.) Singer in which the lentinan content in the fruit body is increased compared with the conventional varieties. In the Lentinus edodes (Berk.) Singer, degradation of the lentinan in the fruit body is inhibited.SELECTED DRAWING: None
OR computing system monitoring is described including self-monitoring and monitoring, with or without intervention, via a monitoring computing system. For a patient procedure in an OR, positions of one or more objects are tracked using sensors. Intra-operative data including pose information is communicated (e.g. in real time) to a monitoring computing system to present the intra-operative data including object positions in a GUI. Pose information may be sensor data with which to calculate a pose of an object or pre-calculated pose data. Intra-operative data may be a workflow state of the procedure to display workflow UI screens. A virtual view of the OR may be presented from pose information and geometric data for OR equipment. Working volumes of OR equipment including collision warning may be presented. OR equipment may include a localizer and/or a robot. Self-monitoring may evaluate progress in a procedure and trigger a request (e.g. to monitor).
INTRODUCTION: Baseline olfactory impairment, poor performance on cognitive test, and medial temporal lobe atrophy are considered biomarkers for predicting future cognitive decline in dementia-free older adults. However, the combined effect of these predictors has not been fully investigated.
METHODS: A group of 110 participants without dementia were continuously recruited into this study, and underwent olfactory, cognitive tests and MRI scanning at baseline and 5-year follow-up. Olfactory function was assessed using the University of Pennsylvania Smell Identification Test (UPSIT). Participants were divided into the cognitive decliners and non-decliners.
RESULTS: Among 87 participants who completed the 5-year follow-up, cognitive decline was present in 32 cases and 55 remained stable. Compared with non-decliners, cognitive decliners presented lower scores on both the UPSIT and the Montreal Cognitive Assessment (MoCA), and smaller hippocampal volume at baseline (all P < .001). The logistic regression analysis revealed that lower scores on UPSIT and MoCA, and smaller hippocampal volume were strongly associated with subsequent cognitive decline, respectively (all P < .001). For the prediction of cognitive decline, lower score on UPSIT performed the sensitivity of 63.6% and specificity of 81.2%, lower score on MoCA with the sensitivity of 74.5% and specificity of 65.6%, smaller hippocampal volume with the sensitivity of 70.9% and specificity of 78.1%, respectively. Combining three predictors resulted in the sensitivity of 83.6% and specificity of 93.7%.
CONCLUSIONS: The combination of olfactory test, cognitive test with structural MRI may enhance the predictive ability for future cognitive decline for dementia-free older adults.
The proposed study is an image acquisition study of mammograms produced by the investigational digital system. Women who meet the selection criteria and who agree to participate in the study will be imaged with the Xpress Digital Mammography System at the clinical sites. These images will be provided to CAD development companies to conduct their own development and testing. The CAD development companies will be responsible for submitting their results to the FDA for marketing approval of their CAD systems.

Patients will be drawn primarily from those women scheduled for breast biopsy since this population has an enhanced probability of cancer. The intent is to enroll patients until at least 107 women with biopsy proven cancers, and at least 330 women who have negative mammograms are enrolled. All cancers found will be used in the study. It is anticipated that approximately 720 patients undergoing diagnostic mammography will need to be enrolled to yield 107 proven cancer cases. In addition, approximately 330 cases will be drawn from a screening population. The negative status of the screening cases will be established by selecting only cases classified as BIRADS 1 or 2, and have a negative mammogram at one year follow-up. All images collected will be utilized to develop and test the CAD systems, and may be used for further product development.
The control group receives programs of Health education (HE) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration will be 90 minutes. They will be trained for 3 times a week over duration of 4 weeks.
The highly specialized and complex technology used in intensive care units to provide continuous monitoring of the patient health context makes possible to increase the survival of patients with critical and unstable clinical status, but increases the triggering factors of the stress of hospitalized patients. Staying in these therapy units is accompanied by additional stress, confusional mental states, cognitive dysfunction, and depression. Virtual reality is a technique that involves the use of computer technology to create the effect of an interactive three-dimensional world in which objects have a spatial presence reducing the suffering related to a medical procedure, without side effects and without the need for additional personnel. Actual exposure to nature can be difficult to achieve for patients admitted to intensive care. Therefore, exposure to nature via media devices, and virtual reality (VR) is considered a promising technology due to its advantage in creating a sense of immersion. Furthermore, some evidence indicates that virtual nature can improve attentional resources, cognitive performance, and pain experience.

This clinical trial aims to analyze the influence of VR use in patients of Intensive Care Unit (ICU). After informed the consent form, participants will be randomly into control and intervention groups. Blood pressure, heart rate, respiratory rate, oxygen saturation will be evaluated, in addition to the experience of well-being and pain immediately before and immediately after the intervention for 2 consecutive days.The hypothesis of the study is that VR will positively influence vital signs and lived experiences, which will consequently reduce the length of stay in the ICU.
The present invention discloses an oral slow-releasing micro-pill of sinomenine and salt thereof, and a preparation method for the oral slow-releasing micro-pill. The sinomenine or the salt thereof of the present invention is composed of an inert core and a coating, wherein the inert core comprises active components with treatment effective dose and pharmaceutic adjuvant, and is coated with the coating. In the present invention, a fluidization process is used for feeding and coating medicine. The aqueous suspension composed of micro powder of sinomenine hydrochloride and a plurality of fillers is used for medicine feeding for the core in a fluidized state, and water dispersion of ethyl cellulose class is preferred for slow-releasing coating in the same fluidizer. A release experiment according to the first law of Chinese pharmacopoeia 2000YEAR edition shows that the sinomenine micro-pill made by the preparation method can release medicine for 12 hours in hydrochloric acid with the pH value of 1.0, or water solution, or phosphate buffer with the pH value of 6.8. The present invention has the advantages of good reproduction and steady and reliable slow-releasing medicine.
The control group was given the same package of placebo,one day before surgery to the sixth day after surgery. The drug is taken orally, 4 capsules at a time, 2 times a day.
The invention discloses medicine for treating lymphoma and a preparation method thereof. The medicine is prepared from, by weight, 30-150 parts of radix bupleuri, 10-50 parts of pericarpium citri reticulatae, 10-50 parts of rhizoma chuanxiong, 10-50 parts of fructus aurantii, 10-50 parts of Chinese herbaceous peony, 10-50 parts of rhizoma atractylodis, 10-50 parts of poria, 10-50 parts of radix angelica sinensis, 30-150 parts of radix et rhizoma rhei and the like. An ethanol extraction and purification technology is adopted, and the raw materials are concentrated and dried into powder and prepared into sugar coated tablets. The medicine is reasonable in formula, multiple types of medicine are matched properly, and the effects of reinforcing the vital essence and strengthening the primordial qi, clearing and activating the channels and collaterals, clearing away heat and toxic materials, activating blood circulation and eliminating swelling are achieved. Through the cooperative or resistant function among the raw materials, the curative effect is improved, the requirement for treatment of complex disease is met, adverse reactions are reduced, the treatment effect is remarkable and lasting, absorption is fast, the effect initiating speed is high, the action is high, and the medicine is free of excitation, safe, reliable, easy to take and capable of radically treating lymphoma and relieving pain of a patient. It is proved through clinical tests that the total effective rate reaches 95%.
PURPOSE: A cosmetic composition containing pH sensitive nanoparticles and biomimetic surfactant is provided to stably maintain skin active ingredients. CONSTITUTION: A cosmetic composition with improved skin permeabiltiy contains pH sensitive nanoparticles and biomimetic surfactant. The pH sensitive nanoparticle is (meth)acrylatic acid or (meth)acrylate compounds. The biomimetic surfactant is phospholipid, glycolipid, fatty acid, lipopeptide, lipoprotein, lipopolysaccharides, or lipid. The skin active ingredient is arbutin, adenosine, niacinamide, or alpha-bisabotol. A method for manufacturing the cosmetic composition comprises step of mixing the pH sensitive nanoparticles and biomimetic surfactant.
Four lesions are selected on each subject for study. A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
A pill dispenser includes a housing and a slidable drawer with a dispenser cup therein. A storage cup is fixed within the housing. The pill dispenser also includes a movable probe, a flexible tip on the probe, and a suction pump in fluid communication with the flexible tip. The pill dispenser may be configured for and/or methods of operating the pill dispenser may include rotating the probe a position above the storage cup, translating the probe downward into the storage cup, and activating the suction pump. While the suction pump is active, the probe is translated to the position above the storage cup, rotated to a position above the dispenser cup, and translated downward into the dispenser cup. The suction pump is deactivated when the flexible tip is within the dispenser cup.
Calibrate a suitable commercial ionization chamber dose calibrator according to the manufacturer's instructions for that particular instrument. An instrument that gives direct radioactivity readouts is recommended.

Use a National Institute of Standards and Technology (NIST) Xenon Xe 133 standard for the initial calibration. Also establish a secondary standard, such as Americium Am 241, at that time for subsequent routine use. Other suitable radionuclides may also be used. Determine the effective readout of the secondary standard compared to the Xenon Xe 133 standard over the range of activities expected for routine measurements. Determine the radioactivities of the dose for administration as follows:

  1. Check the dose calibrator for proper response with the secondary standard.
  2. Insert the Xenon Xe 133 Gas unit dose vial in the dose calibrator and measure the apparent radioactivity of the Xenon Xe 133.
  3. Correct for decay as necessary.



The radioactivity determined by this method is within 25% of the true value. This degree of accuracy includes variations attributed to small differences in geometry and radiation attenuation between the NIST standard ampule and the Xenon Xe 133 Gas unit dose vial.
Participants participating in this study will be connected to eight (8) Portrait Mobile P-SA01PL/P-SP01PL prototype sensors provided by GEHC and two reference monitors, Nellcor N-600X V 1.6.0.0 and a forehead sensor, used as standard operating procedures at the site. Data will be collected using the Portrait Hub patient monitor. The participants are exposed to a desaturation protocol that sequentially decreases the SpO2 in a stepwise fashion. The goal is to achieve six stable oxygenation plateaus between 100 and 70% SpO2, while recording simultaneous SpO2 readings from the prototype and reference devices. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
Grapefruit juice is an inhibitor of the cytochrome P450 (CYP) 3A4 enzyme system, one of the enzyme systems responsible for the metabolism of colchicine. This study will evaluate the effect of multiple daily consumptions of grapefruit juice on the pharmacokinetic profile of a single 0.6 mg dose of colchicine. On study Day 1, after a fast of at least 10 hours twenty-two healthy, non-smoking, non-obese, non-pregnant adult volunteers between the ages of 18 and 45 will be given one dose of colchicine (1 x 0.6 mg tablet). Fasting will continue for 4 hours after the dose. Blood samples will be drawn from all participants before dosing and for 24 hours post-dose on a confined basis at times sufficient to adequately define the pharmacokinetics of colchicine. Blood sampling will continue on a non-confined basis on Days 2-5. After a 14 day washout period, starting on the morning of Day 15 and continuing through Day 17, subjects will return to the clinic for consumption of an administered dose of grapefruit juice (1 x 240 ml) twice daily. On the morning of Day 18 after a fast of at least 10 hours all subjects will receive a co-administered single oral dose of colchicine (1 x 0.6 mg) and grapefruit juice (1 x 240 ml). Fasting will continue for 4 hours after the dose. Blood samples will be drawn from all participants before dosing and for 24 hours post-dose on a confined basis at times sufficient to adequately define the pharmacokinetics of colchicine in the presence of grapefruit juice. Blood sampling will continue on a non-confined basis on Days 19-22. Subjects will consume the final administered dose of grapefruit juice (1 x 240 ml) in the evening on Day 18. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout participation in the study for adverse reactions to the study drug and/or procedures. Seated blood pressure and pulse will be measured prior to dosing and at approximately 1, 2, and 3 hours following drug administration on Days 1 and 18 to coincide with peak plasma concentrations of colchicine. All adverse events whether elicited by query, spontaneously reported, or observed by clinic staff will be evaluated by the Investigator and reported in the subject's case report form.
PROCRIT® (epoetin alfa) is an analogue of erythropoetin, a hormone secreted by kidneys known to stimulate red blood cell production. PROCRIT® is approved to be given three times per week to treat anemia in adult cancer patients receiving chemotherapy. Once per week dosing in adult cancer patients receiving chemotherapy is investigational and is not approved by the FDA. The use of PROCRIT® in children with cancer is investigational and is not approved by the FDA. (Please note: Since completion of this study, once weekly dosing on PROCRIT® in adult cancer patients was approved by FDA in June 2004 and use of PROCRIT® in children with cancer was approved by FDA in October 2005). The use of PROCRIT® to improve quality of life is investigational and not approved by the FDA. This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of once-weekly dosing of PROCRIT® or placebo on anemia in children with cancer undergoing myelosuppressive chemotherapy, and to assess its effect on the quality of life. Patients are randomized into a 1:1 ratio to receive either PROCRIT® or placebo administered intravenously. Randomization is stratified by cancer type, with one stratum for children diagnosed with a malignant solid tumor or Hodgkin's Disease, and the second stratum for children diagnosed with Acute Lymphocytic Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL). The initial dose of study medication is 600 Units/kg for a maximum dose of 40,000 Units intravenously (IV) weekly, or placebo, up to 16 weeks. The study medication is adjusted to 900 Units/kg, for a maximum dose of 60,000 Units IV weekly, if the hemoglobin does not increase by at least 1 g/dL by Study Week 4/5. Patients were seen and evaluated based on the patient's scheduled chemotherapy regimen. Patients who received chemotherapy weekly, every two weeks, or every four weeks (4-week group), scheduled study visits occurred every four weeks. The study investigated effectiveness of once weekly dosing of PROCRIT® on anemia and quality of life in children with cancer undergoing myelosuppressive chemotherapy. The primary measure of effectiveness is the change in the patient-reported Pediatric Quality of Life Inventory (PedsQL Inventory) from baseline to the last assessment. Other measures of effectiveness include differences in hemoglobin levels, transfusion requirements, and quality of life outcomes. Safety is assessed by comparing the incidence and severity of adverse experiences in the PROCRIT® group versus the placebo group. Clinical laboratory tests (hematology, iron profile, and serum chemistry), physical examinations, and vital sign measurements are also assessed. 600 to 900 Units/kg intravenously (IV) of either PROCRIT® or placebo. Initial dose is 600 Units/kg (maximum dose 40,000 Units IV weekly) up to 16 weeks. If the hemoglobin does not increase by \>= 1 g/dL at Week 4/5, dose is adjusted to 900 Units/kg (maximum dose 60,000 Units IV weekly).
An atypical akineto-rigid parkinsonian syndrome, unresponsive to L-dopa has been evidenced in Guadeloupe. Abnormally frequent, this progressive supranuclear palsy (PSP)-like syndrome represents a new clinical entity. Unlike in classical PSP 70% of patients have myoclonus, 59% hallucinations, 78% REM sleep behavior disorders. Oculomotor pattern differs from classical PSP suggesting that cortical dysfunction predominates over brainstem impairments. Neuropathological examination in four patients has shown a widespread accumulation of the tau protein in the basal ganglia, the midbrain and cortical areas.

This syndrome has been associated to the regular consumption of food products derived from plants of the Annonaceae family, more specifically Annona Muricata (soursop), suggesting a toxic origin. We have already confirmed the neurotoxic potential of the lipophilic mitochondrial complex I inhibitor annonacin, the major acetogenin in Annona muricata. This class of compounds is specific to Annonaceae. Nanomolar concentrations of annonacin induce the death of dopaminergic neurons in culture, by impairment of energy production. Chronic systemic intoxication of rats with annonacin causes neuronal damage in the same brain regions that are damaged in patients with atypical parkinsonism. These results greatly suggest that the consumption of annonacea might contribute to the pathogenesis of the disease. The H1 subhaplotype in tau gene associated with PSP in Caucasians did not confer risk for PSP-like atypical parkinsonism in Guadeloupe.
Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
The invention relates to an alpaca source nano antibody and application thereof, in particular to an alpaca source nano antibody combined with SARS-CoV-2RBD and application thereof, comprising a heavy chain variable region, wherein the heavy chain variable region comprises the following CDRs: CDR1 with an amino acid sequence shown as SEQ ID NO. 1, CDR2 with an amino acid sequence shown as SEQ ID NO. 2 and CDR3 with an amino acid sequence shown as SEQ ID NO. 3. The binding constant of the S43 nano antibody and SARS-CoV-2 is 1.2E-10 plus or minus 1.4E-11M, and can effectively inhibit SARS-CoV-2 pseudovirus infection. The S43 nano antibody of the invention has clinical application value in preventing, treating and/or detecting SARS-CoV-2 infection.
Nonclinical studies have shown a retinal toxicity associated with tranexamic acid. Toxicity is characterized by retinal atrophy commencing with changes to the retinal pigmented epithelium and progressing to retinal detachment in cats. The toxicity appears to be dose related, and changes are partially reversible at lower doses. Effects were observed in dogs at oral doses of 800 mg/kg/day and higher (multiple of 11 times the maximum human dose based on body surface area), and in cats at 250 mg/kg/day for 14 days (multiple of 1.6 times the maximum human dose based on body surface area). Some fully reversible changes in pigmentation were observed in cats at doses of 125 mg/kg/day (multiple of 0.8 times the maximum human dose based on body surface area). Studies suggest that the underlying mechanism may be related to a transient retinal ischemia at high exposures, linked to the known sympathomimetic effect of high plasma exposures of tranexamic acid.
Analgesic agents were bupivacaine, morphine, ketorolac and epinephrine. All patients received spinal anesthesia and patient controlled analgesia (PCA) for 24 hours post surgery. The surgical technique and postoperative medication protocols were identical in both groups. The visual analogue scale (VAS) for pain during activity and at rest, and morphine consumption were recorded at 6, 12, 18 and 24 hours postoperatively. LAI-related side effects, blood loss, length of hospital stay, and VAS for satisfaction were monitored. The reviewer was blinded to treatment groups.
A pulmonary diagnostic apparatus includes a personal computer including a memory for storing expected values, each representing a predicted normal level for a pulmonary function. A parameter limit file stores abnormality limits, each related to one of the expected values. A configuration file contains a plurality of degree of severity labels and numerical breakpoints between severity degrees. Finally, a statement data file contains a plurality of textual statements concerning lung functions and diseases or conditions. The three files are operatively associated with the computer. Lung function measuring equipment also is connected to the computer, whereby measured values are compared with the expected values. Based on the comparison, the computer generates an output identifying certain measured values as abnormal, and the degree of abnormality. Also, appropriate statements from the statement data file are generated as output, based upon the comparison. By selectively editing the parameter limit, configuration and statement files, the operator can cause the computer to generate an output corresponding to the operator's preferred analytical approach and syntax.